Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

BeiGene

Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.

Novartis (NVS) Collaborates With BeiGene for Oncology Drug

BeiGene Ltd (NASDAQ: BGNE) announced an option, collaboration, and license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and commercialize BeiGene's ociperlimab in North America, Europe, and Japan.  Ociperlimab is currently being investigated in two global Phase 3 trials, the AdvanTIG-301 and AdvanTIG-302 trials, combined with tislelizumab in lung cancer.

Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1 Billion

Novartis AG (NYSE: NVS) said that its ligelizumab antibody treatment against recurring hives did not meet the goal of superiority to standard treatment Xolair (omalizumab) in a late-stage study. Novartis' PEARL 1 and PEARL 2 Phase 3 studies met the goal for ligelizumab to show higher efficacy against chronic spontaneous urticaria (CSU) compared to placebo at week 12, but not compared to omalizumab.

Novartis' Ligelizumab Suffers Setback In Late-Stage Skin Disorder Studies

BeiGene Ltd. BGNE, +0.25% said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG NVS, -0.20% to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China.

BeiGene to receive up to $1 billion in oncology deal with Novartis

Basel, December 20, 2021 — Novartis announced today the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company's research and development activities in immuno-oncology. Ociperlimab is a late-stage TIGIT inhibitor, a novel class of anti-cancer therapies that blocks the TIGIT protein receptor. Ociperlimab is currently being evaluated in two Phase III lung cancer trials and additional studies are ongoing in a wide range of solid tumors.

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab

Ad hoc announcement pursuant to Art. 53 LR

Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)

Roche Holding AG

Novartis says it will buy back up to $15 billion of its stock, signaling confidence in its growth prospects and its pipeline.

Novartis to Spend Bulk of Roche Windfall on Buying Back Stock, Not M&A

The stock price of Novartis AG (NYSE: NVS) increased by over 3% pre-market today. This is why it happened.

Novartis Stock (NVS): Why The Price Increased Today

Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth and deep pipeline. The buyback is funded through the $20.7 billion Novartis raised by selling its nearly one-third voting stake in Roche Holdings AG (OTC: RHHBY).

Novartis Launches New Share Buyback Program Of Up To $15B

Novartis AG said on Thursday it was launching a new share buyback of up to $15 billion to be executed by the end of 2023, adding it was confident in its top line growth and deep pipeline.

Novartis launches new share buyback of up to $15 billion

Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline

AbbVie

Cardinal Health

Enbridge

Leggett & Platt

MDU Resources Group

Altria

Northwest Natural Gas

Realty Income Corp

Philip Morris

This holiday season, there are many reasons for investors to be joyful and nervous. Very high market valuations could result in years of disappointing returns after a decade of Buffett-like annual returns.

Santa Is Delivering 10 High-Yield Dividend Aristocrat Bargains You Won't Want To Miss

Molecular Partners AG

Molecular Partners AG (NASDAQ: MOLN) entered into a license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies (DARPin-RLTs). According to the license agreement, Novartis will pay $20 million upfront to Molecular Partners.

Molecular Partners Inks License Deal With Novartis For $580M

Basel, December 11, 2021 — Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in the primary analysis (24 weeks) vs. Bosulif®* (bosutinib) were maintained in longer-term follow up for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors (TKIs)1-4.

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Basel, December 11, 2021 — Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular lymphoma (FL) based on a subgroup analysis from an approximately 17-month median follow-up of the pivotal Phase II ELARA study1. These results were presented in an oral session at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) (Abstract #131).

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Novartis is seeing strong interest from private equity investors as well as from other pharmaceuticals companies for the Sandoz generic drugs business it is considering selling, Chief Executive Vas Narasimhan said in a newspaper interview.

Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft

British American Tobacco

Imperial Brands PLC

Red Electrica Corp SA

Sanofi

Swiss Re AG

AT&T

Unilever

Exxon Mobil

Kiplinger "insights for investors" online, first-published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth compiled 7/1/21. 40 European “Dividend Aristocrats,” showed 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats showed 25 years of increases for U.S. companies.

15 Best Dividends On Earth Priced To Buy In December

Basel, December 10, 2021 — Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in analyses from all three cohorts of BYLieve. BYLieve is an ongoing Phase II, open-label, 3-cohort non-comparative study evaluating Piqray with endocrine therapy including men and pre- and postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (mBC) who have progressed on or after prior therapies, including CDK4/6 inhibitor plus endocrine therapy1-5. These data will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) from December 7-10.

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Novartis's potential sale of its Sandoz generic drug business is attracting interest from possible buyers, Chief Executive Vas Narasimhan said in an interview to be published on Friday.

Novartis CEO says Sandoz attracting interest - paper

Novartis AG (NYSE: NVS) has reported the first interpretable results from year two (week 100) of the Phase 3 KESTREL study of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME).  Results from year two of KESTREL were consistent with those seen at year one, including maintenance of best-corrected visual acuity and sustained reductions in central subfield thickness.

Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients

Amgen

VanEck Vectors Biotech ETF

Gilead Sciences

We cover dividend stocks often at 24/7, as they provide investors with much better income streams than U.S.

Biotech Has Been Crushed: 5 Stocks to Buy Now That Pay Big Dividends

Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer and proven overall survival (OS) benefit across patient subgroups. The findings will be presented as a late-breaking oral presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS).

Novartis' New Kisqali Data Shows Consistent Overall Survival Benefit Across Metastatic Breast Cancer Settings

Johnson & Johnson

Pfizer

Eighteen large U.S. and European drug companies will have more than $1.7 trillion in buying power by the end of 2022, according to SVB Leerink analyst Geoffrey Porges. That includes $500 billion in cash, which the companies can use for mergers and acquisitions, to pay down debt or reward shareholders via dividends or share buybacks, the Leerink analyst said.

J&J, Pfizer, Novartis Among Pharma Giants With Biggest War Chests

Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.

Novartis (NVS) Highlights Growth Profile at its R&D Day

Merck

As 2021 winds down, investors may want to keep an eye on several drug companies that hope to get key approvals from the Food and Drug Administration before the year is out. Among the pharmas hoping to get their treatments green-lighted are Argenx SE ( ARGX , Financial), Calliditas Therapeutics AB ( CALT , Financial), Merck & Co. Inc. ( MRK , Financial) and Novartis ( NVS , Financial).

Merck, Novartis in Line for Key FDA Approvals This Month

News for Novartis Stock (NVS)